Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016.

MLA

Rudà, Roberta, et al. “Efficacy of Initial Temozolomide for High-Risk Low Grade Gliomas in a Phase II AINO (Italian Association for Neuro-Oncology) Study: A Post-Hoc Analysis within Molecular Subgroups of WHO 2016.” Journal of Neuro-Oncology, vol. 145, no. 1, Oct. 2019, pp. 115–23. EBSCOhost, https://doi.org/10.1007/s11060-019-03277-x.

APA

Rudà, R., Pellerino, A., Pace, A., Carapella, C. M., Dealis, C., Caroli, M., Faedi, M., Bello, L., Migliore, E., Marchese, G., Bertero, L., Cassoni, P., & Soffietti, R. (2019). Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016. Journal of Neuro-Oncology, 145(1), 115–123. https://doi.org/10.1007/s11060-019-03277-x

Chicago

Rudà, Roberta, Alessia Pellerino, Andrea Pace, Carmine Maria Carapella, Cristina Dealis, Manuela Caroli, Marina Faedi, et al. 2019. “Efficacy of Initial Temozolomide for High-Risk Low Grade Gliomas in a Phase II AINO (Italian Association for Neuro-Oncology) Study: A Post-Hoc Analysis within Molecular Subgroups of WHO 2016.” Journal of Neuro-Oncology 145 (1): 115–23. doi:10.1007/s11060-019-03277-x.